Aubrey Kudzala

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

James Hakim, Cissy Kityo, Anne Hoppé et al. · The Lancet Infectious Diseases · 2017 · 41 citations · Full text

Pharmacy, Infectious Disease Control, Pharmacotherapy +17

“It reminds me and motivates me”: Human-centered design and implementation of an interactive, SMS-based digital intervention to improve early retention on antiretroviral therapy: Usability and acceptability among new initiates in a high-volume, public clinic in Malawi

Jacqueline Huwa, Hannock Tweya, Maryanne Mureithi et al. · PLoS ONE · 2023 · 25 citations · Full text

Public Health, Community Health, Health Informatics +16

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

Cissy Kityo, David Dunn, Anne Hoppé et al. · Clinical Infectious Diseases · 2018 · 12 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +17

The effect of proactive, interactive, two-way texting on 12-month retention in antiretroviral therapy: Findings from a quasi-experimental study in Lilongwe, Malawi

Caryl Feldacker, Robin E. Klabbers, Jacqueline Huwa et al. · PLoS ONE · 2024 · 11 citations · Full text

Public Health, Community Health, Health Services Research +16